Cargando…

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been linked to late-onset AD and other neurodegenerative disorders. TREM2, a microg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henjum, Kristi, Almdahl, Ina S., Årskog, Vibeke, Minthon, Lennart, Hansson, Oskar, Fladby, Tormod, Nilsson, Lars N. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848774/ https://www.ncbi.nlm.nih.gov/pubmed/27121148 http://dx.doi.org/10.1186/s13195-016-0182-1

Ejemplares similares

Analyzing microglial-associated Aβ in Alzheimer’s disease transgenic mice with a novel mid-domain Aβ-antibody
por: Henjum, Kristi, et al.
Publicado: (2020)

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
por: Edwin, Trine Holt, et al.
Publicado: (2020)

Cerebrospinal fluid sTREM2 in Alzheimer’s disease: comparisons between clinical presentation and AT classification
por: Knapskog, Anne-Brita, et al.
Publicado: (2020)

The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway
por: Jendresen, Charlotte, et al.
Publicado: (2017)

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
por: Hertze, Joakim, et al.
Publicado: (2014)

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
por: Heslegrave, Amanda, et al.
Publicado: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

Association of rs2062323 in the TREM1 gene with Alzheimer's disease and cerebrospinal fluid‐soluble TREM2
por: Wang, Zuo‐Teng, et al.
Publicado: (2023)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
por: Liu, Changan, et al.
Publicado: (2019)

Association between Cerebrospinal Fluid Soluble TREM2, Alzheimer’s Disease and Other Neurodegenerative Diseases
por: Zhou, Wenchuan, et al.
Publicado: (2023)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Cerebrospinal fluid markers in Creutzfeldt-Jakob disease
por: Skinningsrud, Anders, et al.
Publicado: (2008)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer’s Disease
por: Španić Popovački, Ena, et al.
Publicado: (2023)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup
por: Woollacott, Ione O. C., et al.
Publicado: (2018)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
por: Silajdžić, Edina, et al.
Publicado: (2012)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2014)

Cerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease
por: Henjum, Kristi, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Glial activation and inflammation along the Alzheimer’s disease continuum
por: Nordengen, Kaja, et al.
Publicado: (2019)

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
por: Björkqvist, Maria, et al.
Publicado: (2012)

Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2022)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
por: Hertze, Joakim, et al.
Publicado: (2013)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

[(18)F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [(18)F]-Fludeoxyglucose
por: Kalheim, Lisa Flem, et al.
Publicado: (2018)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
por: Stomrud, Erik, et al.
Publicado: (2010)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h49j2sq155s7pcrtdbvm3t8enj